Carfilzomib and Codeine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Carfilzomib (carfilzomib) and Codeine (codeine sulfate). Common drug interactions include diarrhoea among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Carfilzomib and Codeine. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Carfilzomib?

Carfilzomib has active ingredients of carfilzomib. eHealthMe is studying from 13,486 Carfilzomib users. Check the latest studies of Carfilzomib.

What is Codeine?

Codeine has active ingredients of codeine sulfate. It is often used in pain. eHealthMe is studying from 42,342 Codeine users. Check the latest studies of Codeine.



On Aug, 06, 2026

25 people who take Carfilzomib and Codeine together, and have interactions are studied.

Carfilzomib and Codeine drug interactions.

What are the common drug interactions of Carfilzomib and Codeine, by gender? *:

female:

  1. Diarrhoea
  2. Device related infection
  3. Salmonellosis (an infection with salmonella bacteria)
  4. Colorectal cancer (colon cancer or bowel cancer)
  5. Pyrexia (fever)
  6. Herpes zoster
  7. Stomatitis (inflammation of mucous membrane of mouth)
  8. Thrombocytopenia (decrease of platelets in blood)
  9. Anaemia (lack of blood)
  10. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

male:

  1. Platelet count decreased
  2. Stomatitis (inflammation of mucous membrane of mouth)
  3. Laryngeal inflammation (infection of larynx)
  4. Lymphocyte count decreased
  5. Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
  6. Bacteraemia (presence of bacteria in the blood)
  7. Blood creatinine increased
  8. Enterocolitis infectious
  9. Escherichia bacteraemia (presence of bacteria escherichia coli in the blood)
  10. Gamma-glutamyltransferase increased

What are the common drug interactions of Carfilzomib and Codeine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Platelet count decreased
  2. Stomatitis (inflammation of mucous membrane of mouth)
  3. Infection
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  5. Plasma cell myeloma (cancer that begins in plasma cells)
  6. Urinary tract infection
  7. Anaemia (lack of blood)
  8. Dyspnoea (difficult or laboured respiration)
  9. Hypoxia (low oxygen in tissues)
  10. Laryngeal inflammation (infection of larynx)

60+:

  1. Diarrhoea
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Angina pectoris (chest pain due to ischemia of the heart muscle)
  4. Blood bilirubin increased
  5. Hyperkalaemia (damage to or disease of the kidney)
  6. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  7. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
  8. Renal impairment (severely reduced kidney function)
  9. Second primary malignancy (after getting cure a cancer, a new cancer development)
  10. Pyrexia (fever)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 19 people, 76.00%
  2. High Blood Pressure: 6 people, 24.00%
  3. The Flu (the flu is caused by an influenza virus): 5 people, 20.00%
  4. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 5 people, 20.00%
  5. Cough: 5 people, 20.00%
  6. Enlarged Prostate: 4 people, 16.00%
  7. Atypical Pneumonia (acute respiratory disease marked by high fever and coughing): 4 people, 16.00%
  8. Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 3 people, 12.00%
  9. Mucosal Inflammation (infection of mucous membrane): 3 people, 12.00%
  10. Depression: 3 people, 12.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carfilzomib and Codeine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Carfilzomib and Codeine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Carfilzomib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Codeine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Carfilzomib and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Codeine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib and codeine sulfate (the active ingredients of Carfilzomib and Codeine, respectively), and Carfilzomib and Codeine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: